Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after =5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after =5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY Wakelee, H. A., Altorki, N. K., Zhou, C., Csoszi, T., Vynnychenko, I. O., Goloborodko, O., Rittmeyer, A., Reck, M., Martinez-Marti, A., Kenmotsu, H., Chen, Y., Chella, A., Sugawara, S., Fu, C., Ballinger, M., Deng, Y., Srivastava, M. K., Bennett, E., Gitlitz, B., Felip, E. 2024; 42 (17_SUPPL): LBA8035View details for DOI 10.1200/JCO.2024.42.17_suppl.LBA8035
View details for Web of Science ID 001244441000035